Compare MobilEye Global Inc (MBLY) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MobilEye Global Inc vs TransMedics Group Inc — how do they compare? MobilEye Global Inc trades at $9.03 (market cap $7.54B), while TransMedics Group Inc trades at $74.78 (market cap $2.54B). The key difference: MobilEye Global Inc is far larger — about 3× TransMedics Group Inc's market cap, and MobilEye Global Inc is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| MBLY | TMDX | |
|---|---|---|
Market Cap | $7.54B | $2.54B |
Sector | Technology | Technology |
52-Week High | $16.19 | $150.42 |
52-Week Low | $6.56 | $61.99 |
Enterprise Value | $6.19B | $2.94B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mobileye (MBLY) trades at $8.95, down 2.93% on the day, with a bearish technical signal and mixed earnings history. The company reported a net loss of $392 million in 2025 despite revenue of $1.89 billion, reflecting negative profit margins. Recent news highlights its strategic shift toward launching a vertically integrated U.S. robotaxi service in 2027, generating significant media attention and analyst coverage.
The outlook hinges on execution of its robotaxi initiative, offering growth potential but carrying high execution risk. Analyst consensus is bullish with a $10.71 price target, yet profitability challenges and competitive pressures pose substantial risks. Investors should weigh the long-term transformation against current financial weakness.
TransMedics (TMDX) trades at $73.47, down 0.69% with neutral technical signals. The stock shows strong profitability with 27% net margins and 45% ROE, though Q1 2026 earnings missed expectations. Recent strategic investment in European aviation logistics aims to expand the Organ Care System platform. Analyst consensus remains bullish with a $108.71 price target representing 48% upside potential.
Long-term growth prospects appear solid given TMDX's expanding transplant ecosystem, but near-term margin pressure from expansion investments and execution risks warrant caution. The company maintains competitive advantages in organ transplant logistics, though increased spending and competitive threats from alternatives like Strata Critical Medical present headwinds for shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MobilEye Global Inc
Mobileye Global Inc. is a global leader in the development and deployment of Advanced Driver Assistance Systems (ADAS) and autonomous driving technologies. The company specializes in computer vision, machine learning, and data analysis to create sensing, mapping, and driving policy solutions. Mobileye's technology, including its EyeQ system-on-chips and its crowd-sourced mapping platform (REM), is integrated into vehicles worldwide, aiming to improve road safety and enable the future of autonomous mobility.
Read more on MBLY →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
